Literature DB >> 7574544

Antiviral resistance in clinical practice.

D W Kimberlin1, C S Crumpacker, S E Straus, K K Biron, W L Drew, F G Hayden, M McKinlay, D D Richman, R J Whitley.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7574544     DOI： 10.1016/0166-3542(95)00031-g

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  5 in total

1.  Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

Authors:  Jianmin Duan; Michel Liuzzi; William Paris; Francine Liard; Abigail Browne; Nathalie Dansereau; Bruno Simoneau; Anne-Marie Faucher; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Anti-HSV activity of serpin antithrombin III.

Authors:  Debra C Quenelle; Tracy L Hartman; Robert W Buckheit; Mark N Prichard; Ralf Geiben Lynn
Journal:  Int Trends Immun       Date:  2014-04

3.  Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Authors:  J Duan; M Liuzzi; W Paris; M Lambert; C Lawetz; N Moss; J Jaramillo; J Gauthier; R Déziel; M G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

4.  Antiviral activity of (+)-sattabacin against varicella zoster.

Authors:  Serena R Mancha; Christopher M Regnery; Joshua R Dahlke; Kenneth A Miller; David J Blake
Journal:  Bioorg Med Chem Lett       Date:  2012-11-16       Impact factor: 2.823

5.  Anti-herpes virus activity of the carnivorous botanical, Sarracenia purpurea.

Authors:  Latha Kannan; Ashok Kumar; Aradhana Kumar; Bertram Jacobs; Jeffrey Langland
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.